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Abstract
Tumor necrosis factor-related apoptosis-induced li-
gand (TRAIL) induces apoptosis selectively in cancer 
cells while sparing normal cells. However, many can-
cer cells are resistant to TRAIL-induced cell death. 
Here, we report that paxilline, an indole alkaloid from 
Penicillium paxilli, can sensitize various glioma cells 
to TRAIL-mediated apoptosis. While treatment with 
TRAIL alone caused partial processing of caspase-3 to 
its p20 intermediate in TRAIL-resistant glioma cell 
lines, co-treatment with TRAIL and subtoxic doses of 
paxilline caused complete processing of caspase-3 in-
to its active subunits. Paxilline treatment markedly 
upregulated DR5, a receptor of TRAIL, through a 
CHOP/GADD153-mediated process. In addition, paxil-
line treatment markedly downregulated the protein lev-
els of the short form of the cellular FLICE-inhibitory 
protein (c-FLIPS) and the caspase inhibitor, survivin, 
through proteasome-mediated degradation. Taken to-
gether, these results show that paxilline effectively 
sensitizes glioma cells to TRAIL-mediated apoptosis 
by modulating multiple components of the death re-
ceptor-mediated apoptotic pathway. Interestingly, 
paxilline/TRAIL co-treatment did not induce apoptosis 
in normal astrocytes, nor did it affect the protein levels 
of CHOP, DR5 or survivin in these cells. Thus, com-
bined treatment regimens involving paxilline and 
TRAIL may offer an attractive strategy for safely treat-
ing resistant gliomas.
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Introduction
Tumor necrosis factor-related apoptosis-induced 
ligand (TRAIL), a member of the TNF family, in-
duces apoptosis in diverse tumor cell types but not 
in normal cells, and is therefore considered a po-
tential anticancer agent (Sheridan et al., 1997; 
Ashkenazi et al., 1999). When TRAIL cross-links 
with its death receptors, DR4 or DR5, the death 
receptors oligomerize and trigger the recruitment of 
Fas-Associated protein with Death Domain (FADD), 
the activation of caspase-8, and the subsequent 
initiation of apoptosis (Kischkel et al., 2000). How-
ever, recent studies have shown that many cancer 
cells, including glioma cells, are resistant to TRAIL- 
induced apoptosis even though they express 
TRAIL receptors (Hao et al., 2001; Kim et al., 
2005). Thus, the development of new therapeutic 
strategies to restore TRAIL-induced apoptosis in 
cancer cells will be required to improve the efficacy 
of TRAIL-based cancer therapy.
    Malignant gliomas, which are the most common 
primary brain tumors, are notoriously resistant to 
traditional therapeutic strategies, such as surgery, 
radiation therapy, and chemotherapy (Weller, 1986). 
Increasing evidence suggests that resistance to 
apoptosis is a fundamental mechanism through 
which gliomas evade elimination in the face of 
conventional or targeted treatments (Ziegler et al., 
2008). Recent studies have shown that inhibition of 
ion channels or pumps has provided a potential 
new approach for biochemical therapy of the brain 
tumors (Yin et al., 2007; Lefranc and Kiss, 2008) 
and inhibition of ion channels or pumps can 
increase the sensitivity of cancer cells to TRAIL 
(He et al., 2002; Kaddour-Djebbar et al., 2006; 
Monteith et al., 2007). Paxilline, an indole alkaloid 
from Penicillium paxilli, inhibits the activity of lar-
ge-conductance Ca2+-activated K+ channels (BK 
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channels) (Sanchez and McManus, 1996) and the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) 
(Bilmen et al., 2002). Here, we show for the first 
time that subtoxic doses of paxilline can sensitize 
TRAIL-resistant glioma cells to TRAIL-induced ap-
optosis, while sparing normal astrocytes. Further-
more, we provide evidence that CHOP-mediated 
DR5 upregulation, survivin downregulation and 
c-FLIP downregulation may all contribute to the 
glioma-selective killing effects of paxilline/TRAIL 
co-treatment.
Results
Paxilline recovers TRAIL sensitivity in various glioma 
cells by inducing caspase-mediated apoptosis 
To examine whether paxilline sensitizes various 
glioma cells to TRAIL-induced cell death, we 
treated four glioma cell lines (U251MG, U87MG, 
U343, and U251N) with paxilline alone, TRAIL 
alone, or both paxilline and TRAIL for 24 h at 
various concentrations. Assessment of cellular 
viability using calcein-AM and EthD-1 to detect live 
and dead cells, respectively, revealed that treat-
ment with TRAIL alone up to 100 ng/mL or paxilline 
alone up to 30 μmol/L did not induce significant cell 
death in U251MG or U87MG cells (Figure 1A). 
However, paxilline/TRAIL co-treatment effectively 
induced cell death, when we fixed the paxilline 
concentration and varied the TRAIL concentration, 
and vice versa. U343 and U251N cells were more 
sensitive to TRAIL than U251MG and U87MG 
cells, but co-treatment of U343 and U251N cells 
with subtoxic doses of paxilline markedly en-
hanced TRAIL-induced cell death. An isobologram 
analysis demonstrated that paxilline and TRAIL 
synergistically induced cell death in all four tested 
glioma cell lines (Figure 1B). Next, we investigated 
whether caspases were critically involved in this 
paxilline/TRAIL-induced cell death. Pretreatment of 
U251MG cells with z-VAD-fmk (a pancaspase 
inhibitor), z-IETD-fmk (a caspase-8 inhibitor), or 
z-DEVD-fmk (a caspase-3 inhibitor) significantly 
and dose-dependently inhibited cell death in 
co-treated cells (Figure 1C). Further examination 
revealed that treatment of U251MG cells with 30 
μmol/L paxilline alone did not induce any pro-
teolytic processing of caspase-8 or -3 (Figure 1D). 
Caspase-8 was not processed in response to 
TRAIL alone, but it was effectively processed fol-
lowing the combined treatment. Interestingly, treat-
ment with TRAIL alone caused partial processing 
of caspase-3 to its p20 intermediate, whereas 
co-treatment with TRAIL and subtoxic doses of 
paxilline caused complete processing of caspase-3 
into its active subunits. Both Bid (a substrate of 
caspase-8) and PARP (a substrate of caspase-3) 
were effectively cleaved by paxilline plus TRAIL, 
but not by either alone. Analysis of caspase-3 
activity using the fluorometric substrate, DEVD- 
AFC (7-amino-4-trifluoromethyl coumarin) showed 
that caspase-3 activity was very weakly increased 
by 100 ng/mL TRAIL alone, whereas it was mark-
edly increased by 24 h after co-treatment with 
paxilline and TRAIL (Figure 1E). These results 
suggest that the TRAIL-mediated partial priming of 
pro-caspase-3 into its p20 intermediate form was 
insufficient to trigger casapse-3 activity. But, co- 
treatment with paxilline completed this partial pro-
cessing into the active p17 and p12 subunits, 
yielding caspase-3 activity. Flow cytometric an-
alysis showed that the hypodiploid sub-G1 cell 
population was markedly increased by the com-
bined treatment of U251MG cells with 30 μmol/L 
paxilline plus 100 ng/mL TRAIL, but not by either 
alone (Figure 1F). Taken together, these results 
demonstrate that paxilline enhances the TRAIL 
sensitivity of glioma cells by inducing caspase- 
mediated apoptosis. 
Upregulation of DR5 and downregulation of c-FLIP 
and survivin are common responses to paxilline in 
malignant glioma cells
To explore the underlying mechanisms involved in 
paxilline-stimulated TRAIL-mediated apoptosis, we 
examined the expressions of various apoptotic 
regulators in U251MG cells treated with paxilline 
alone. Paxilline treatment increased the protein 
levels of the TRAIL receptor, DR5, but not those of 
DR4 (Figure 2A). Although paxilline treatment did 
not alter the protein levels of XIAP and Bcl-2, it 
triggered the downregulation of survivin (a caspase 
inhibitor) and c-FLIP (the caspase-8 inhibitor) ma-
jor isoforms, c-FLIPS and c-FLIPL, were both 
strongly downregulated. To confirm that these ef-
fects were a common response to paxilline in 
glioma cells, we tested the effects of various doses 
of paxilline on the levels of these proteins in other 
cell lines. Paxilline dose-dependently increased the 
protein levels of DR5, but decreased those of 
c-FLIPL, c-FLIPS and survivin in all tested glioma 
cells lines, including U251MG, U87MG, U343 and 
U251N cells (Figure 2B). These results suggest 
that DR5, c-FLIPS, c-FLIPL and survivin could be 
involved in paxilline-mediated sensitization of glio-
ma cells to TRAIL-mediated apoptosis. 
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Upregulation of DR5 and downregulation of c-FLIP 
and survivin play important roles in the paxilline- 
triggered enhancement of TRAIL-induced apoptosis 
Next, we investigated whether DR5, c-FLIP and 
survivin are critically involved in the apoptosis 
induced by paxilline and TRAIL. First, to clarify the 
functional significance of DR5 upregulation, we 
employed siRNA against DR5. We found that 
transfection with the DR5-specific siRNA effectively 
inhibited the cell death induced by paxilline/TRAIL 
co-treatment (Figure 3A). Next, to examine whe-
ther the cell death induced by paxilline plus TRAIL 
was affected by the overexpression of c-FLIPS or 
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Figure 1. Paxilline and TRAIL synergistically induce apoptosis in malignant glioma cells.  (A) Cells were treated with paxilline for 30 min and further treated with 
TRAIL for 24 h at the indicated concentrations. Cellular viability was assessed using calcein-AM and EthD-1. Columns, mean; bars, SD. *, P＜0.01 vs. control; †, P
＜0.01 vs. cell treated with TRAIL alone. (B) Cells were treated for 24 h with various concentrations of paxilline and/or TRAIL, and an isobologram analysis was per-
formed as described in the “Methods” section. (C) U251MG cells were treated with specific caspase inhibitors at the indicated concentrations for 30 min, and further 
treated with 30 μmol/L paxilline and 100 ng/mL TRAIL for 24 h. Cellular viability was assessed using calcein-AM and EthD-1. Columns, mean; bars, SD. *, P＜0.01 
vs. control; †, P＜0.01 vs. cells treated with paxilline plus TRAIL. (D) Cell extracts were prepared from U251MG cells treated with 30 μmol/L paxilline and/or 100 
ng/mL TRAIL for the indicated time points, and Western blotting was used to detect the levels of the indicated proteins. Equal protein loading was confirmed by 
Western blotting of α-tubulin. (E) U251MG cells were treated with 100 ng/mL TRAIL with or without 30 μmol/L paxilline for the indicated time points. Caspase-3 activ-
ity (RFU, relative fluorescence units) was measured using a fluorometric assay kit, as described in the “Methods” section. The data shown are representative of three 
independent experiments. Points, mean; bars, SD. (F) U251MG cells were treated with 30 μmol/L paxilline and/or 100 ng/mL TRAIL for 16 h, and the cellular DNA 
contents were examined by flow cytometric analysis.
Figure 2. Subtoxic doses of paxilline commonly induce upregulation of 
DR5 and downregulation of FLIP and survivin in various glioma cells. (A) 
U251MG cells were treated with 30 μmol/L paxilline for the indicated time 
points and Western blotting was done to detect the levels of the indicated 
proteins. Equal loading was confirmed by Western blotting of α-tubulin. 
(B) Cells were treated with 30 μmol/L paxilline for the indicated time 
points and Western blotting was used to detect the levels of the indicated 
proteins. 
c-FLIPL, we established cell lines that stably 
overexpressed c-FLIPS or c-FLIPL and examined 
their responses to paxilline/TRAIL co-treatment. 
We found that both proteins blocked co-treat-
ment-induced caspase-3 activation and cell death, 
with c-FLIPS overexpression showing a stronger 
blocking effect than c-FLIPL overexpression (Fig-
ure 3B). Similarly, overexpression of survivin in 
U251MG cells also attenuated the caspase-3 
activation and cell death induced by paxilline/ 
TRAIL co-treatment (Figure 3C). To further assess 
whether the downregulation of c-FLIP and/or 
survivin was critical for paxilline-mediated TRAIL- 
induced apoptosis, we employed siRNAs against 
c-FLIPS, c-FLIPL and survivin. We found that 
siRNA-mediated suppression of c-FLIPS enhanced 
caspase-3 activity and cell death more markedly 
than suppression of c-FLIPL in U251MG cells 
treated with 100 ng/mL TRAIL (Figure 3D). Si-
milarly, siRNA-mediated suppression of survivin 
expression effectively enhanced caspase-3 activity 
and cell death in U251MG cells treated with TRAIL 
(Figure 3E). Taken together, these findings collec-
tively suggest that the upregulation of DR5 and the 
downregulation of c-FLIP (particularly c-FLIPS) and 
survivin all contribute to the paxilline-triggered 
enhancement of TRAIL-mediated cell death.
In paxilline-treated cells, CHOP mediates DR5 
upregulation, while proteasomes mediate the 
downregulation of c-FLIP and survivin  
We then investigated the potential mechanisms 
underlying the paxilline-induced modulation of 
DR5, c-FLIP and survivin expression. First, we 
examined whether their expression levels were 
transcriptionally controlled. RT-PCR analysis de-
monstrated that paxilline dose-dependently in-
creased the mRNA levels of DR5, but not c-FLIPS, 
c-FLIPL or survivin (Figure 4A). Since the CHOP 
transcription factor has been associated with the 
transcription of DR5 (Yoshida et al., 2005), we 
tested the possible involvement of CHOP in 
paxilline-induced DR5 upregulation. We found that 
paxilline treatment increased CHOP protein levels 
prior to the upregulation of DR5 (Figure 4B). We 
then used a luciferase reporter system containing 
the DR5 promoter to test whether CHOP was 
directly involved in the paxilline-mediated trans-
criptional activation of the DR5 promoter. The 
pDR5-605 plasmid contained 605-bp of the up-
stream DR5 promoter sequence, while the pDR- 
605-mCHOP plasmid contained the same sequen-
ce harboring mutations in the CHOP-binding site 
(Figure 4C). Paxilline treatment increased the 
promoter activity of pDR5-605 but not that of 
pDR5-605-mCHOP (Figure 4C), suggesting that 
abrogation of the CHOP-binding site blocked the 
paxilline-induced activation of the DR5 promoter. 
The functional significance of CHOP in paxil-
line-induced DR5 upregulation was further ex-
amined using CHOP-specific siRNA. Our results 
revealed that siRNA-mediated suppression of 
CHOP significantly inhibited the paxilline-induced 
upregulation of DR5 (Figure 4D). Moreover, the 
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siRNA-mediated knockdown of CHOP significantly 
attenuated the paxilline-induced increase in ca-
spase-3 activity and death of U251MG cells treated 
with 100 ng/mL TRAIL. Collectively, these results 
show that CHOP-mediated DR5 upregulation may 
contribute to the ability of paxilline to recover 
TRAIL sensitivity in TRAIL-resistant glioma cells.
    Since our RT-PCR analysis showed that the 
mRNA levels of c-FLIPL, c-FLIPS and survivin were 
unaffected by paxilline treatment (Figure 4A), we 
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Figure 3. DR5, c-FLIP and survivin are critically involved in the paxilline-stimulated TRAIL-mediated apoptosis of glioma cells. (A) U251MG cells were 
transfected with 40 nmol/L fluorescent oligonucleotide (F-Oligo; control) or 40 nmol/L siRNA duplexes against the DR5 mRNA, incubated for 24 h, and fur-
ther treated with or without 30 μmol/L paxilline plus 100 ng/mL TRAIL for 24 h. Cellular viability was assessed using calcein-AM and EthD-1 (left). 
Columns, mean; bars, SD. *, P＜ 0.01 vs. untreated cells; †, P＜ 0.01 vs. cells tansfected with F-Oligo and treated with paxilline plus TRAIL. Cells 
were transfected with the siRNA, incubated for 24 h, and then subjected to Western blotting of DR5 (right). (B & C) Effect of overexpression of c-FLIP or 
survivin on the apoptosis induced by paxilline plus TRAIL. (a) Stable cell lines overexpressing pcDNA3, c-FLIPS, c-FLIPL or survivin were established and 
the overexpression of each protein was confirmed by Western blotting. (b) The stably overexpressing cells were treated with 30 μmol/L paxilline and 100 
ng/mL TRAIL for 24 h, and cellular viability was analyzed using calcein-AM and EthD-1. Columns, mean; bars, SD. *, P＜ 0.01 vs. untreated control; †, 
P＜ 0.01 vs. control cells treated with paxilline plus TRAIL. (c) Caspase-3 activity was measured as described in the “Methods” section. Columns, mean; 
bars, SD. *, P＜ 0.01 vs. untreated control; †, P＜ 0.01 vs. control cells treated with paxilline plus TRAIL. (D & E) Effect of siRNA-mediated sup-
pression of c-FLIP or survivin. (a) U251MG cells were transfected with 40 nmol/L fluorescent oligonucleotide (F-Oligo), siRNAs against c-FLIPS, c-FLIPL or 
survivin. Twenty-four hours after transfection, knockdown of the relevant proteins was confirmed by Western blotting. (b) To examine the effect of c-FLIP 
or survivin downregulation on TRAIL-induced cell death, U251MG cells were transfected with each siRNA, incubated for 24 h, and further treated with or 
without 100 ng/mL TRAIL for 24 h. Cellular viability was assessed using calcein-AM and EthD-1. Columns, mean; bars, SD. †, P＜ 0.01 vs. control cells 
transfected with F-Oligo and further treated with TRAIL. (c) Caspase-3 activity was assessed as described in the “Methods” section. Columns, mean; 
bars, SD. †, P＜ 0.01 vs. control cells transfected with F-Oligo and further treated with TRAIL.
tested whether the paxilline-induced downregula-
tions of c-FLIP and survivin were associated with 
proteasome-mediated degradation. We found that 
pretreatment with the proteasome inhibitor, MG132, 
dose-dependently recovered the paxilline-induced 
suppression of c-FLIPL, c-FLIPS and survivin (Fig-
ure 4E). These findings indicate that paxilline 
downregulates c-FLIP and survivin via protea-
some-mediated degradation.
Paxilline/TRAIL co-treatment does not induce cell 
death in normal astrocytes 
Finally, we examined the effect of paxilline/TRAIL 
co-treatment on the viability of normal human 
astrocytes. We found that astrocytes were resistant 
to TRAIL or paxilline alone, as well as to pa-
xilline/TRAIL co-treatment (Figure 5A), suggesting 
that paxilline/TRAIL co-treatment is preferentially 
toxic to glioma cells over normal astrocytes. While 
caspase-3 was partially processed into its p20 
intermediate form in TRAIL-treated U251MG cells, 
and further processed into its active subunits in 
paxilline/TRAIL co-treated cells, no such process-
ing was observed in TRAIL-treated or paxilline/ 
TRAIL co-treated astrocytes (Figure 5B). Paxilline- 
treated astrocytes showed no evidence of CHOP 
upregulation, DR5 upregulation, survivin down-
regulation, or c-FLIPL downregulation, whereas the 
levels of c-FLIPS were slightly reduced in these 
cells (Figure 5C). Taken together, our results 
collectively suggest that the TRAIL-mediated part-
ial priming of caspase-3 and the paxilline-mediated 
modulation of various components in the death 
receptor-mediated apoptotic signaling pathways 
(e.g., DR5, c-FLIP and survivin) may allow pa-
xilline/TRAIL co-treatment to selectively kill glioma 
cells, while sparing normal astrocytes (Figure 5D).
Discussion
Here, we show for the first time that paxilline may 
be used as an effective TRAIL sensitizer in 
malignant glioma cells, and further explore the 
potential mechanisms underlying this effect. Our 
results revealed that paxilline facilitated the pro-
teolytic processing of caspase-3 in glioma cells 
exposed to TRAIL via downregulation of c-FLIP 
and survivin. c-FLIP, a homolog of caspase-8, is 
recruited to the death-inducing signaling complex, 
where it inhibits the activation of caspase-8 (Irmler 
et al., 1997). We found that the protein levels of 
c-FLIPS were more markedly reduced than those of 
c-FLIPL in paxilline-treated glioma cells, and ex-
periments involving the overexpression or siRNA- 
mediated downregulation of c-FLIPS and c-FLIPL 
demonstrated that changes in c-FLIPS appear to 
contribute to paxilline-induced TRAIL sensitization 
more than changes in c-FLIPL. Survivin is ex-
pressed more highly in cancer tissues than in 
normal tissues (Ambrosini et al., 1997), and cancer 
patients with upregulated survivin have been 
shown to have shortened survival, more un-
favorable markers of disease progression, ac-
celerated rates of recurrence (Altieri, 2001) and 
increase resistance to therapy (Kato et al., 2001). 
Here, we found that paxilline treatment dose-de-
pendently reduced the protein levels of survivin in 
various glioma cells. Furthermore, siRNA-mediated 
survivin knockdown increased TRAIL-mediated 
apoptosis in U251MG cells, whereas survivin over-
expression significantly attenuated the cell death 
induced by paxilline plus TRAIL. To exclude the 
possibility that these findings could have been 
affected by clonal variability among the stably 
transfected cell lines, we transiently overexpressed 
survivin, c-FLIPS and c-FLIPL, and examined the 
cell death induced by paxilline/TRAIL co-treatment. 
Consistent with the above findings, survivin, c- 
FLIPS and c-FLIPL dose-dependently attenuated 
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Figure 4. Paxilline induces CHOP-mediated DR5 upregulation and proteasome-mediated downregulation of c-FLIP and survivin. (A) U251MG cells were 
treated with the indicated concentrations of paxilline and total RNA was prepared for RT-PCR of the indicated gene products, with β-actin assessed as an 
internal control. (B) U251MG cells were treated with 30 μmol/L paxilline for the indicated time points and the indicated proteins were detected by Western 
blotting. (C) Schematic diagram of the DR5 promoter constructs used for the luciferase activity assays (top). U251MG cells were transfected with 
pDR5-605 or pDR5-605-mCHOP, treated with 30 μmol/L paxilline, lysed, and assayed for luciferase activity (bottom). Data are expressed as fold-change 
relative to the untreated cells transfected with pDR5-605. Columns, mean; bars, SD. *, P＜ 0.01 vs. cells transfected with pDR5-605 and untreated. (D) 
U251MG cells were transfected with 40 nmol/L F-Oligo or siRNA duplexes against the CHOP mRNA, and incubated for 24 h. (a) Western blotting was 
used to confirm CHOP knockdown and examine its effect on paxilline-induced DR5 upregulation. Equal loading of protein samples was confirmed by 
Western blotting of α-tubulin. (b) Transfected cells were treated with or without or 30 μmol/L paxilline plus 100 ng/mL TRAIL for 24 h, and cellular viability 
was assessed using calcein-AM and EthD-1. Columns, mean; bars, SD. *, P＜ 0.01 vs. cells transfected with F-Oligo and untreated; †, P＜ 0.01 vs. 
cells transfected with F-Oligo and treated with paxilline plus TRAIL. (c) Caspase-3 activity was assessed as described in the “Methods” section. Columns, 
mean; bars, SD. *, P＜ 0.01 vs. cells transfected with F-Oligo and untreated; †, P＜ 0.01 vs. control cells transfected with F-Oligo and treated with pax-
illine plus TRAIL. (E) U251MG cells were treated with 30 μmol/L paxilline with or without the indicated concentrations of MG132 for 12 h. Western blotting 
was used to assess changes in the protein levels of c-FLIPL, c-FLIPS and survivin.
paxilline/TRAIL-induced cell death (Supplemental 
Data Figures S1 and S2) and the death-blocking 
effect of c-FLIPS was stronger than that of c-FLIPL 
(Supplemental Data Figure S2). Furthermore, pre-
treatment of U251MG cells with the proteasome 
inhibitor, MG132, effectively blocked the paxilline- 
induced downregulation of c-FLIPS, c-FLIPL and 
survivin (Figure 4E). These findings collectively 
indicate that paxilline stimulates TRAIL-mediated 
apoptosis in glioma cells via the proteasome- 
dependent degradation of c-FLIP and survivin. 
Interestingly, treatment with TRAIL alone induced 
the partial proteolytic processing of caspase-3 to 
its p20 intermediate form and weakly increased the 
caspase-3 activity in U251MG cells, demonstrating 
that caspase-3 activation was partially primed in 
TRAIL-treated glioma cells (Figures 1D, 1E, and 
5B). Co-treatment with paxilline and TRAIL led to 
the further processing of caspase-3 into its p17 
and p12 subunits. Based on this, we speculate that 
the paxilline-triggered proteasome-mediated de-
gradation of c-FLIP may reduce the barriers li-
miting the efficient formation of the death-inducing 
signaling complex (DISC), thereby enhancing the 
activation of caspase-8. In addition, the paxil-
line-induced degradation of survivin may further 
facilitate the complete proteolytic processing of 
caspase-3, which is partially processed by TRAIL 
treatment. 
    Paxilline is known to inhibit BK channels (San-
chez and McManus, 1996) and various isoforms of 
SERCA, with IC50 values of 5 to 50 μmol/L (Bilmen 
et al., 2002). Recent studies have shown that BK 
channel activation is involved in the proliferation of 
diverse cancer cells, including glioma cells (Bloch 
et al., 2007; Coiret et al., 2007), and the ex-
pression levels of BK channels have been closely 
correlated with the grades of glioma malignancy 
(Weaver et al., 2004). Thapsigargin, a well-known 
SERCA inhibitor (Lytton et al., 1991), was pre-
viously shown to potentiate TRAIL-induced apop-
tosis in giant cell bone tumor, perhaps by per-
turbing intracellular Ca2+ homeostasis (Huang et 
al., 2004). In addition, SERCA inhibition increased 
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Figure 5. Combined treatment with paxilline and TRAIL does not induce 
cell death in normal astrocytes. (A) Human astrocytes were treated with 
paxilline for 30 min and further treated with the indicated concentrations
of TRAIL for 24 h. Cellular viability was assessed using calcein-AM and 
EthD-1. Columns mean; bars, SD (left). Astrocytes were treated with 30 
μmol/L paxilline and/or 100 ng/mL TRAIL for 24 h. Representative pic-
tures are shown (right). (B & C) Astrocytes or U251MG cells were treated 
with 30 μmol/L paxilline and/or 100 ng/mL TRAIL for 24 h, and cell ex-
tracts were subjected to Western blotting of the indicated proteins. (D) 
Schematic diagram of the apoptotic pathway that appears to be induced 
by paxilline and TRAIL co-treatment of glioma cells.
[Ca2+]i more quickly and to a higher degree in 
glioma cells compared to normal astrocytes (Ko-
vacs et al., 2005). Therefore, we examined whe-
ther the sensitizing effect of paxilline on TRAIL- 
mediated apoptosis in glioma cells was associated 
with the inhibition of BK channels and/or SERCA. 
We found that subtoxic doses of two SERCA 
inhibitors, thapsigargin (Huang et al., 2004) and 
cyclopiazonic acid (Goeger et al., 1988), effectively 
sensitized U251MG cells to TRAIL-induced cell 
death, whereas two BK channel inhibitors, ibe-
riotoxin (Galvez et al., 1990) and penitrem A 
(Knaus et al., 1994), did not (Supplemental Data 
Figure S3A). Furthermore, treatment with thap-
sigargin or cyclopiazonic acid dose-dependently 
downregulated c-FLIP and survivin, but upregu-
lated CHOP and DR5 (Supplemental Data Figure 
S3B), in a manner similar to that seen for paxilline 
(Figure 2B). In previous studies, thapsigargin- 
induced downregulation of survivin (Sohn et al., 
2003) and alpha-TEA (RRR-alpha-tocopherol eth-
er-linked acetic acid analog)-induced downregula-
tion of c-FLIPL (Tiwary et al., 2010) were shown to 
involve endoplasmic reticulum (ER) stress. Since 
inhibition of SERCA activity has been shown to 
induce ER stress by causing intracellular Ca2+ 
imbalances (Lytton et al., 1991), we examined 
whether paxilline could induce the unfolded protein 
response (an indicator of ER stress) in our system. 
We found that paxilline treatment increased KDEL 
protein levels and eIF2α phosphorylation (Supple-
mental Data Figure S4), in addition to increasing 
CHOP levels (Figure 4B). Taken together, our 
findings collectively show that the sensitizing effect 
of paxilline on TRAIL-mediated apoptosis may be 
closely associated with SERCA inhibition, which 
may cause ER stress and subsequent CHOP 
upregulation. This CHOP-dependent DR5 upregu-
lation may amplify the death receptor-mediated 
apoptotic signaling in glioma cells exposed to both 
paxilline and TRAIL. However, future work will be 
required to clarify the potential relationships among 
SERCA inhibition, proteasome-mediated degrada-
tion, and the downregulation of c-FLIP and sur-
vivin.
    In cancer therapy, success often depends on 
both effectively killing cancer cells and maintaining 
the safety of normal cells. Here, we found that 
normal astrocytes were very resistant to treatment 
with paxilline and TRAIL, both alone and in 
combination (Figure 5A). Furthermore, astrocytes 
did not show evidence of the observed TRAIL- 
induced partial processing of caspase-3 (Figure 
5B), paxilline-induced downregulation of c-FLIP 
and survivin, or paxilline-induced upregulation of 
DR5 (Figure 5C). These findings suggest that 
astrocytes are doubly protected from the death- 
inducing activities of paxilline/TRAIL co-treatment. 
    In summary, the present study shows that 
paxilline is capable of modulating multiple targets 
in the death receptor-mediated apoptotic signaling 
pathway, including DR5, c-FLIP and survivin, 
thereby selectively sensitizing glioma cells to 
TRAIL-induced apoptosis. Thus, paxilline and 
TRAIL co-treatment may offer a safe and effective 
strategy for selectively killing malignant glioma 
cells.
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Methods
Chemicals and antibodies 
Paxilline was purchased from Sigma-Aldrich Corporation 
(St. Louis, MO). Recombinant human TRAIL (the non-
tagged 19 kDa protein, amino acids 114-281) was from 
KOMA Biotech (Seoul, South Korea). Calcein acetoxy-
methyl ester (calcein-AM) and ethidium homodimer-1 
(EthD-1) were from Invitrogen (Carlsbad, CA). Caspase 
inhibitor benzyloxy-carbonyl-Val-Ala-Asp-(OMe)-fluoromethyl 
ketone (z-VAD-fmk), benzyloxy-carbonyl-Asp-(OMe)-Glu- 
(OMe)-fluoromethyl ketone (z-DEVD-fmk), and benzyloxy- 
carbonyl-Ile-Glu-(OMe)-Tyr-Asp-(OMe)-fluoromethyl 
ketone (z-IETD-fmk) were from R&D system (Minneapolis, 
MN). The following antibodies were used: anti-caspase-3, 
-survivin, and -XIAP (Stressgen, British Columbia, Ca-
nada); anti-DR4, -CHOP/growth arrest and damage-in-
ducible gene 153 (GADD153), and -Bcl-2 (Santa Cruz 
Biotechnology, Santa Cruz, CA); anti-c-FLIP (Alexis, San 
Diego, CA); anti-cleaved PARP (Poly (ADP-ribose) poly-
merase) (Epitomics, Burlingame, CA); anti-Bid (Cell Sig-
naling, Beverly, MA); anti-α-tubulin and DR5 (KOMA Bio-
tech); horseradish peroxidase-conjugated anti-rabbit IgG 
and horseradish peroxidase-conjugated mouse IgG (Invi-
trogen). 
Culture of glioma cell lines and normal human 
astrocytes 
The human malignant glioma cell lines U251MG, U87MG, 
U343, and U251N were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and antibiotics (GIBCO-BRL, Grand 
Island, NY). Primary cultures of normal human astrocytes 
were prepared from 14-week fetal cerebrum tissues, as 
described previously (Kim et al., 1986). Human astrocytes 
were cultured in high-glucose DMEM supplemented with 
10% FBS and 20 mg/mL gentamicin. The cells were 
subcultured every two weeks, and cell cultures of five or 
fewer passage were used. 
Measurement of cellular viability 
Cells (3.5× 104 cells) were cultured in 24-well plates and 
treated as indicated. The test drugs were then removed 
and the cells were washed twice with PBS. For mea-
surement of cellular viability, 200 μL of 2 μmol/L cal-
cein-AM (which indicates intracellular esterase activity with 
a green fluorescence that was taken as a representing 
living cells) and 4 μmol/L EthD-1 (which indicates mem-
brane-damaged cells with a red fluorescence that was 
taken as indicating dead cells) were added to each well, 
and the plates were incubated for 30 min in a moist 
chamber at room temperature. The cells were then viewed 
under a fluorescence microscope (Axiovert 200M, Carl 
Zeiss, Germany) equipped with a Zeiss filter set #10 
(excitation/emission wavelengths of 450-490/515-565 nm) 
and #34 (excitation/emission wavelengths of 390/460 nm). 
The numbers of green, red, and bicolored cells were 
counted from five fields per well at 400× magnification. 
The percentage of cells with exclusively green fluore-
scence (viable cells) was calculated.
Flow cytometry to measure apoptosis
DNA content was assessed using Cell Cycle TEST PLUS 
DNATM reagent kit (Becton Dikinson and Co., San Jose, 
CA), according to the manufacturer’s instruction, and 
analyzed in a FACS sorter (Becton Dikinson and Co.). 
Fluorometric assay of caspase-3 activity
Caspase-3 activity was assayed with a caspase-3/CPP32 
fluorometric assay kit (Biovision, CA). Cells (2× 105 cells) 
were cultured in 6-well plates and treated. The cells were 
then harvested, washed twice with cold PBS, and re-
suspended with cell lysis buffer following the instructions 
provided with the assay kit. The protein concentrations of 
the cell lysates were determined using Bio-Rad protein 
assay (Bio-Rad Laboratories, Berkeley, CA), and 80 μg of 
total protein from each sample was mixed with a reaction 
buffer containing the caspase-3 fluorogenic substrate, 
DEVD-AFC (7-amino-4-trifluoromethyl coumarin). The sam-
ples were incubated for 1 h at 37oC, and the results were 
obtained using a fluorescence microplate reader (Mole-
cular Devices, CA) at excitation/emission wavelengths of 
400/505 nm. To compare the caspase-3 activity levels 
among the different treatment groups, the fold increases in 
caspase-3 activity were determined by comparing the 
absorbance from each apoptotic sample with that from the 
corresponding untreated control.     
Reverse transcription-PCR analysis 
Total RNA was extracted from U251MG cells using the 
TRIzol reagent (Invitrogen). Reverse transcription-PCR 
(RT-PCR) was done, following the manufacturer’s protocol 
(TaKaRa Shuzo Co., Otsu, Shiga, Japan). The cDNAs 
were amplified by PCR (30 s at 94oC, 30 s at 60oC, and 1 
min 74oC) with Taq DNA polymerase. Conditions for final 
analysis were chosen when amplification of mRNA was in 
the middle of the exponential amplification phase for 30 
μmol/L paxilline tested. Human DR5 mRNA was amplified 
using the sense primer 5'-GTCTGCTCTGATCACCCAAC- 
3' and the antisense primer 5'-CTGCAAACTGTGACTCCT-
ATG-3' (corresponding to a 424-bp region of DR5). For 
c-FLIPL, the sense primer 5'-CGGACTATAGAGTGCTGA-
TGG-3' and the antisense primer 5'-GATTATCAGGCA-
GATTCCTAG-3' (corresponding to a 655-bp region of 
c-FLIPL), and for c-FLIPS, the sense primer 5'-CGGACT-
ATAGAGTGCTGATGG-3' and the antisense primer 5'- 
AGATCAGGACAATGGGCATAG-3' (corresponding to a 561- 
bp region of c-FLIPS) were used. For survivin, the sense 
primer 5'-CAGATTTGAATCGCGGGACCC-3' and the anti-
sense primer 5'-CCAGAGTCTGGCTCGTTCTCAG- 3' (cor-
responding to a 206-bp region of survivin). For β-actin, the 
sense primer 5'-CAGGTCATCACCATTGGCAATGAGC-3' 
and the antisense primer 5'-GATGTCCACGTCACACT-
TCATGA-3' (corresponding to a 132-bp region of β-actin) 
were used. The PCR cycling conditions (30 cycles) chosen 
were as follows: (a) 30 s at 94oC; (b) 45 s at 52oC for 
CHOP, 30 s at 68oC for DR5, 30 s at 55oC for c-FLIPS, 30 s 
at 56oC for c-FLIPL, and 1 min at 60oC for survivin, 30 s at 
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60oC for β-actin; (c) 1 min 30 s at 72oC, with a subsequent 
10 min extension at 72oC. Reaction products were an-
alyzed on 2% agarose gels. The bands were visualized by 
ethidium bromide.
Small interfering RNA 
25-nucleotide small interfering RNA (siRNA) duplexes 
used in this study were purchased from Invitrogen and 
have the following sequences: DR5 (E11), AUCAGCAUC-
GUGUACAAGGUGUCCC; CHOP, UUCACCAUUCGGUC-
AACAGAGCUC; c-FLIPS, AACAUGGAAC UGCCUCUA-
CUU; c-FLIPL, AAGGAACAGCUUGGCGCUCAA; survivin, 
UUUAAGGCUGGGAGCCAGAUGACGC. BLOCK-IT Fluo-
rescent Oligo (Invitrogen) was used as the control. Cells 
were transfected with siRNA oligonucleotides using Li-
pofectamine 2000 (Invitrogen) according to the manu-
facturer’s recommendations.
Plasmids, transfection, and luciferase assay 
The pDR5/-605 plasmid [containing DR5 promoter se-
quence (-605/+3)] was a gift from Dr. T. Sakai (Kyoto 
Prefectural University of Medicine). CHOP-binding sites in 
the DR5/-605 promoter were point mutated using a two- 
step PCR method and mCHOP primers (5'-CTTGCG-
GAGGAGGTAGTTGACGA and 5'-TCGTCAACTACCTC-
CTCCGCAAG). The resulting mutant was confirmed by 
sequencing. For transfection, cells (3× 105 cells) were 
plated onto 60-mm culture dishes, grown overnight, and 
then transfected with 1 μg of the indicated luciferase re-
porter construct using the Lipofectamine Plus reagent 
(Invitrogen). After incubation for 24 h, the transfected cells 
were further treated with or without 30 μmol/L paxilline, 
and their luciferase and β-galactosidase activities were 
assayed following the manufacturer’s protocol (Promega, 
Madison, WI). The activity of luciferase was normalized 
with regard to that of β-galactosidase, and the results are 
given as the average of three independent experiments. 
Overexpression of c-FLIPS, c-FLIPL, or survivin
U87MG cells were transfected with a vector containing 
Flag-tagged c-FLIPS, c-FLIPL (kindly provided by Dr. Park 
SI, Korea Centers for Disease Control and Prevention, 
Korea), or survivin (kindly provided by Dr. JS Lee, Ajou 
University, Korea). Overexpression of c-FLIP or survivin 
was analyzed by Western blotting using anti-c-FLIP 
(Alexis) and anti-survivin (Stressgen) antibody.
Statistical analysis
All data are presented as means± SD from at least three 
independent experiments. The statistical significance of 
differences was assessed using an analysis of variance 
with Bonferroni correction or a repeated-measures analysis 
of variance followed by Greenhouse-Geisser adjustment. 
Values of P＜ 0.05 were considered significant. The 
synergy of paxilline and TRAIL was evaluated by the 
isobologram method (Berenbaum, 1981). In brief, the cells 
were treated with different concentrations of each agent 
(paxilline or TRAIL) alone or in combination. The relative 
survival was assessed, and the IC50 (the half maximal 
inhibitory concentration) values for each drug alone or in 
combination with a fixed concentration of the second agent 
were established from the concentration-effect curves. In a 
graphical presentation, the straight line connecting the IC50 
values of the two agents when applied alone corresponds 
to the additive effects of both agents. Values below this line 
indicate synergy, while values above this line indicate 
antagonism.
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